Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Less: comprehensive income attributable to noncontrolling interest

Less: comprehensive income attributable to noncontrolling interest at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
——

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's less: comprehensive income attributable to noncontrolling interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's less: comprehensive income attributable to noncontrolling interest?
Charles River Laboratories (CRL) reported less: comprehensive income attributable to noncontrolling interest of -$393K in Q1 2026.
How has Charles River Laboratories's less: comprehensive income attributable to noncontrolling interest changed year-over-year?
Charles River Laboratories's less: comprehensive income attributable to noncontrolling interest increased by 12.5% year-over-year, from -$449K to -$393K.
What is the long-term trend for Charles River Laboratories's less: comprehensive income attributable to noncontrolling interest?
Over 2 years (2023 to 2025), Charles River Laboratories's less: comprehensive income attributable to noncontrolling interest has grown at a -14.3% compound annual growth rate (CAGR), from $4.55M to $3.34M.